1-14 of 14
Calvin Lee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Gilles Salles, Franck Morschhauser, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný, Georg Lenz, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Graham P. Collins, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Calvin Lee, Saibah Chohan, Matthew Sugidono, Yanwen Jiang, Connie Lee Batlevi, Mark Yan, Jamie Hirata, Hervé Tilly, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 469.
https://doi.org/10.1182/blood-2024-197938
Published: 2024
Journal Articles

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Fabrice Jardin, Vibha Raghavan, Samuel Tracy, Sandhya Balasubramanian, Laurie H. Sehn, Christopher R. Flowers, Franck Morschhauser, Alex F. Herrera, Marek Trněný, Jeff P. Sharman, Gilles Salles, Hervé Tilly, Jonathan W. Friedberg, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Georg Lenz
Journal: Blood
Blood (2023) 142 (Supplement 1): 169.
https://doi.org/10.1182/blood-2023-178564
Published: 2023
Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Franck Morschhauser, Wilfred Leung, Vibha Raghavan, Georg Lenz, Fabrice Jardin, Alex F. Herrera, Laurie H. Sehn, Jeff P. Sharman, Christopher R. Flowers, Jonathan W. Friedberg, Marek Trněný, Hervé Tilly, Charles Herbaux, Samuel Tracy, Christopher R. Bolen, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Gilles Salles
Journal: Blood
Blood (2023) 142 (Supplement 1): 3000.
https://doi.org/10.1182/blood-2023-178623
Published: 2023
Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Clinical Trials & Observations
Yuqin Song, Hervé Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Hideki Goto, Yasuhito Terui, Ho-Jin Shin, Won Seog Kim, Junning Cao, Jifeng Feng, Hyeon Seok Eom, Tae Min Kim, Xavier Cheng-Hong Tsai, Jyh-Pyng Gau, Hideo Koh, Liling Zhang, Yongping Song, Yu Yang, Wei Li, He Huang, Kiyoshi Ando, Jeff P. Sharman, Laurie H. Sehn, Lilian Bu, Xin Wang, Yanwen Jiang, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu
Journal: Blood
Blood (2023) 141 (16): 1971–1981.
https://doi.org/10.1182/blood.2022017734
Published: 2023
Includes: Supplemental data
Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Alex F. Herrera, Ronald McCord, Patrick Kimes, Fabrice Jardin, Georg Lenz, Marek Trneny, Christopher R. Flowers, Laurie H. Sehn, Gilles Salles, Jeff P. Sharman, Hervé Tilly, Jonathan W. Friedberg, Charles Herbaux, Matthew J. Matasar, Corinne Haioun, Samuel Tracy, Jamie Hirata, Calvin Lee, Yanwen Jiang, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 1297–1300.
https://doi.org/10.1182/blood-2022-157559
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
https://doi.org/10.1182/blood-2022-157761
Published: 2022
Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6645–6647.
https://doi.org/10.1182/blood-2022-157904
Published: 2022
Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan Miguel Bergua Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta Costa, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2021-154729
Published: 2021
Journal Articles

Adenine Base Editing of the Sickle Allele in CD34 + Hematopoietic Stem and Progenitor Cells Eliminates Hemoglobin S

S. Haihua Chu, PhD, Daisy Lam, Michael S. Packer, PhD, Jennifer Olins, Alexander Liquori, Jeffrey Marshall, PhD, Calvin Lee, Bo Yan, PhD, Jeremy Decker, Bob Gantzer, M.S., Scott J. Haskett, M.S., Tanggis Bohnuud, PhD, David Born, PhD, Luis Barrera, PhD, Ian Slaymaker, PhD, Nicole M. Gaudelli, PhD, Adam J. Hartigan, PhD, Giuseppe Ciaramella, PhD, B.Sc.
Journal: Blood
Blood (2020) 136 (Supplement 1): 47.
https://doi.org/10.1182/blood-2020-141805
Published: 2020
Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 883.
https://doi.org/10.1182/blood-2019-123450
Published: 2019
Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, MD, Herve Tilly, Gilles Salles, MD PhD, Lijia Wang, Calvin Lee, Jeffrey P. Sharman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4120.
https://doi.org/10.1182/blood.V130.Suppl_1.4120.4120
Published: 2017
Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 1853.
https://doi.org/10.1182/blood.V128.22.1853.1853
Published: 2016
Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1856.
https://doi.org/10.1182/blood.V128.22.1856.1856
Published: 2016
Journal Articles

Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition

Tessa Knox, MS, Maritza Lienlaf, MS, Patricio Perez-Villarroel, BS., Calvin Lee, MD, Eva Sahakian, PhD, John J. Powers, B.S., Fengdong Cheng, MD, Jorge Canales, MS, Danay Marante, MS, Ed Seto, PhD, Eduardo M. Sotomayor, MD, Alejandro Villagra, PhD, Pedro Horna, MD
Journal: Blood
Blood (2014) 124 (21): 5423.
https://doi.org/10.1182/blood.V124.21.5423.5423
Published: 2014